Evidence map›Paper›PMID 31450922›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

Prognostic Significance of Cyclin D1 Over-expression in Colorectal Cancer: An Experience from Madinah, Saudi Arabia.

Abdulkader Mohammed Albasri, Mohammed Aboulmatty Elkablawy, Irfan Altaf Ansari, Ahmed Safar Alhujaily

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Integrating network pharmacology and Mendelian randomization to explore potential targets of matrine against ovarian cancer.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024
    Article
  4. Article
  5. Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  6. Article
  7. The Effect of Avidin on Viability and Proliferation of Colorectal Cancer Cells HT-29.Asian Pacific journal of cancer prevention : APJCP · 2022
    Article
  8. Article
  9. StandardizedFrontiers in pharmacology · 2021
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Abdulkader Mohammed AlbasriDepartment of Pathology, Taibah University, Universities Road, Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Email: abdbasri@hotmail.com
Mohammed Aboulmatty ElkablawyDepartment of Pathology, Taibah University, Universities Road, Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Email: abdbasri@hotmail.com
Irfan Altaf AnsariDepartment of Pathology, Taibah University, Universities Road, Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia. Email: abdbasri@hotmail.com
Ahmed Safar AlhujailyDepartment of Pathology, King Fahd Hospital, Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia.
Taibah University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and study aim: Cyclin D1 is a key regulatory protein in the cell cycle and is over-expressed in many tumors, including endometrial, thyroid, urothelial, breast, brain gliomas, and esophageal cancers. The main aim of the present study is to examine the expression pattern of cyclin D1 and its correlation with the different clinicopathological features in patients with colorectal camcer (CRC) from the Madinah region of Saudi Arabia. Patients and methods: The archival tumor blocks were analyzed using immunohistochemistry for Cyclin D1 over-expression in 324 CRC patients diagnosed from January 2006 to December 2017, at the Department of Pathology, King Fahad Hospital, Madinah, Saudi Arabia. Results: Cyclin D1 over-expression was absent in normal mucosa, while 15% cases of adenoma showed its over-expression. In CRC, Cyclin D1 was expressed at high levels in 24.1% of case. No significant correlation was observed between Cyclin D1 over-expression and age, gender, tumor size, type and location. However, Cyclin D1 over-expression exhibited a significant correlation with tumor differentiation (p=0.04), lymph node involvement (p=0.001), lymphovascular invasion (p=0.001), distant metastasis (p=0.006) and AJCC staging (p=0.001). The Kaplan-Meir analysis revealed a shorter period of survival with Cyclin D1 over-expression (p=0.000). The Cox-regression model analysis showed that Cyclin D1 over-expression was an independent prognostic marker in CRC (p=0.000). Conclusion: Cyclin D1 over-expression increases during normal-adenoma-carcinoma sequence. The significant association observed between Cyclin D1 over-expression, advanced tumor stage and short survival period clearly suggest the role of Cyclin D1 in the carcinogenesis and progression of CRC.

Indexed as

AdenomaAdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsCyclin D1FemaleFollow-Up StudiesHumansLymphatic MetastasisMaleMiddle AgedNeoplasm InvasivenessPrognosisBiomarkers, TumorCCND1 protein, humanCyclin D1cancercolorectalCyclin D1Prognosis

Identifiers

PMID31450922
PMCPMC6852817
OpenAlexW2969546856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.